Literature DB >> 15464063

Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.

Miriam Andrés1, Ana Peña, Sylvain Derick, Danièle Raufaste, Jerzy Trojnar, Kazimierz Wisniewski, Miguel Trueba, Claudine Serradeil-Le Gal, Gilles Guillon.   

Abstract

In this study, we characterized the bovine vasopressin V(1a), V(1b), V(2) receptor isoforms and compared their pharmacological properties to those of corresponding rat and human vasopressin receptor subtypes. Specific binding sites of high affinity for vasopressin were found in all bovine tissues tested (kidney, liver and pituitary). Using a large series of recent peptidic and non-peptidic selective vasopressin agonists or antagonists, we demonstrated the presence of vasopressin V(2), V(1a) or V(1b) receptors in the kidney, liver and pituitary bovine tissues, respectively. This extensive characterization of bovine vasopressin receptor isoforms validates the pharmacological vasopressin receptor classification earlier established for the rat and human species. As expected, the bovine vasopressin receptors look much more like human receptors than rat ones. Interestingly, among the three vasopressin receptor isoforms studied, the vasopressin V(1b) receptor subtype is the best conserved for the three species studied.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464063     DOI: 10.1016/j.ejphar.2004.08.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 2.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

3.  A Self-Assembling Lipidic Peptide and Selective Partial V2 Receptor Agonist Inhibits Urine Production.

Authors:  Sunish Patel; Antonella Bavuso Volpe; Sahar Awwad; Andreas G Schätzlein; Shozeb Haider; Boqian Liu; Ijeoma F Uchegbu
Journal:  Sci Rep       Date:  2020-04-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.